🧫
RBG treatment in ApoE-/- atherosclerosis mouse model
active
experiment
Created: 2026-04-11T00:50:00
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-9d2d59a7-8bc0-4399-aab0-2538f3a07b6f
🧫 Experiment Protocol
ValidationatherosclerosisNLRP3,APOEApoE-/- miceproposed
This experiment investigated the therapeutic effects of Resibufogenin (RBG) on atherosclerosis progression in ApoE-/- mice, a well-established model for studying atherosclerosis. The study assessed RBG's ability to reduce atherosclerotic plaque formation, improve lipid profiles, and modulate inflammatory responses. Mice were treated with RBG and various parameters were measured including body weight, atherosclerotic plaque size, serum lipid profiles, and inflammatory marker expression. The experiment demonstrated that RBG treatment effectively alleviated atherosclerosis symptoms by reducing plaque formation and improving metabolic parameters.
PRIMARY OUTCOME
atherosclerotic plaque size and inflammatory markers
EXPECTED OUTCOMES
RBG treatment was expected to reduce atherosclerotic plaque formation and inflammatory responses. Results showed reduced body weight, smaller atherosclerotic plaques, improved serum lipid profiles, and suppressed expression of inflammatory markers including NLRP3
SUCCESS CRITERIA
reduction in plaque size, improved lipid profiles, decreased inflammatory markers
PROTOCOL
ApoE-/- mice were treated with RBG, followed by assessment of body weight, atherosclerotic plaque formation, serum lipid profiles, and inflammatory marker expression through transcriptomics and molecular biology techniques
LINKED HYPOTHESES
h-44195347· APOE4 Allosteric Rescue via Small Molecule Chaperonesh-d0a564e8· Competitive APOE4 Domain Stabilization Peptidesh-11795af0· Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)h-99b4e2d2· Interfacial Lipid Mimetics to Disrupt Domain Interactionh-a20e0cbb· Targeted APOE4-to-APOE3 Base Editing Therapy
Source: PMID 40258472 ↗
🧫 Experiment Extras
PATHWAY
NLRP3 inflammasome,inflammation,lipid metabolism
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.